Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/20/2005US20050232998 Dry powder inhalant composition
10/20/2005US20050232995 Administering oral dosage forms that comprise benzisoxazole derivative and dosing structures or sustainable releasing means that provide specified release profiles or specified pharmacokinetic characteristics such as substantially ascending rate of release; atypical antipsychotics; reduced side effects
10/20/2005US20050232994 Dual-spike release formulation for oral drug delivery
10/20/2005US20050232993 Dosage form containing promethazine and another drug
10/20/2005US20050232992 Proton pump inhibitor formulations, and methods of preparing and using such formulations
10/20/2005US20050232991 Storage stable thyroxine active drug formulations and methods for their production
10/20/2005US20050232990 Donepezil formulations
10/20/2005US20050232989 Process for preparing oral calcium compositions
10/20/2005US20050232988 Orally disintegrating tablets and methods of manufacture
10/20/2005US20050232987 Dosage form containing a morphine derivative and another drug
10/20/2005US20050232986 Dosage form containing promethazine and another drug
10/20/2005US20050232985 Ciprofloxacin hcl
10/20/2005US20050232984 Non-vesicular cationic lipid formulations
10/20/2005US20050232983 Transdermal patch
10/20/2005US20050232982 drug layer, support layer insoluble in water comprising ethyl cellulose and hydroxypropyl methylcellulose, backing on support layer, wherein drug layer consists of fentanyl or salt as active ingredient, methyl vinyl ether-maleic anhydride copolymer as adhesive, hydroxypropylcellulose; easily removed
10/20/2005US20050232980 Transdermal chondroitin and glucosamine delivery system and method of use
10/20/2005US20050232978 Delivery system for topical medications
10/20/2005US20050232975 Composition and method to improve quality and yield of meat products
10/20/2005US20050232972 Drug delivery via punctal plug
10/20/2005US20050232970 prosthesis, stent medical device has a multilayer with bioactive agent-releasing coatings having heparin activity; coatings are formed using biostable or biodegradable polymeric material and photoreactive groups; absorbs light at different wavelength, without hurting the bioactive agent
10/20/2005US20050232969 Methods of treatment with Syk inhibitors
10/20/2005US20050232965 Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
10/20/2005US20050232957 Compositions and methods for moisturizing skin
10/20/2005US20050232952 Self emulsifying drug delivery systems for poorly soluble drugs
10/20/2005US20050232928 Drug conjugates
10/20/2005US20050232925 Protease activity of thrombin inhibits angiogenesis
10/20/2005US20050232923 Methods and compositions for treating MCP-1 related pathologies
10/20/2005US20050232916 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
10/20/2005US20050232915 Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
10/20/2005US20050232911 Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
10/20/2005US20050232908 Novel use of the extract of processed ginseng and saponin isolated therefrom
10/20/2005US20050232902 Injectable bioartificial tissue matrix
10/20/2005US20050232895 Anti-viral pharmaceutical compositions
10/20/2005US20050232891 Methods of treating skin with diphosphonate derivatives
10/20/2005US20050232879 Antifungal medicinal compositions
10/20/2005US20050232874 Compound and method of treatment for fungal pathologies of the oral cavity
10/20/2005US20050232873 Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
10/20/2005US20050232872 Compositions and methods for enhancing receptor-mediated cellular internalization
10/20/2005US20050232871 Use of compounds in a dry powder inhaler
10/20/2005US20050232870 Method of treatment of dopamine-related dysfunction
10/20/2005US20050232869 Aerosol packages; mixture containing water, hydrophobic solvent, surfactants and gelling agent; compressed gas propellant
10/20/2005US20050232868 In situ administering into nasal cavities; mixture of flow control agents and deactivating compound
10/20/2005US20050232867 include a permeation enhancer, that is, a material which is capable of increasing the rate of passage of the peptide through the nasal mucosa
10/20/2005US20050232862 Combination therapy for the treatment of estrogen-sensitive drugs
10/20/2005US20050232860 Use of edg-receptor agonists for the treatment of hypertension
10/20/2005US20050231646 Circuit for processing video signal including information such as caption
10/20/2005US20050230067 Mosquito curtain
10/20/2005DE20221397U1 Transdermal-Pflaster zum Verabreichen von Fentanyl Transdermal patch for administering fentanyl
10/20/2005DE10393805T5 Pharmazeutische Formulierungen, die ß-2-Adrenorezeptor-Agonisten und Xantine enthalten Included Pharmaceutical formulations beta-2-adrenoreceptor agonists and Xantine
10/20/2005CA2853272A1 Synthesis of boronic ester and acid compounds
10/20/2005CA2829943A1 Ion binding compositions
10/20/2005CA2806465A1 Ion binding polymers and uses thereof
10/20/2005CA2774121A1 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
10/20/2005CA2677470A1 Methods of treatment using eszopiclone
10/20/2005CA2677465A1 Methods of treatment using eszopiclone
10/20/2005CA2567574A1 Benzotriazine inhibitors of kinases
10/20/2005CA2565324A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005CA2563541A1 D-homo-17-chloro-16(17)ene steroids
10/20/2005CA2563502A1 Novel water-soluble prodrug
10/20/2005CA2563316A1 Pten inhibitors
10/20/2005CA2563123A1 Selective antagonists of a2a adenosine receptors
10/20/2005CA2563033A1 Novel gamma secretase inhibitors
10/20/2005CA2562965A1 Nucleoside derivatives and therapeutic use thereof
10/20/2005CA2562954A1 Biologically active compounds with anti-angiogenic properties
10/20/2005CA2562399A1 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005CA2562371A1 Diarylamine derivatives as calcium channel blockers
10/20/2005CA2562231A1 Active substance combination of a carbinol compound and an opioid
10/20/2005CA2562219A1 Active substance combination comprising a carbinol combined to at least an nsaid
10/20/2005CA2562140A1 Phenylthioacetic acid derivatives and use thereof
10/20/2005CA2562015A1 Intermittent dosing regimens of apob secretion/mtp inhibitors for overweith and obese subjects
10/20/2005CA2562009A1 (r,r)-formoterol in combination with other pharmacological agents
10/20/2005CA2562004A1 Sinapic acid supplementation
10/20/2005CA2561967A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005CA2561958A1 Composition and method for inhibiting platelet aggregation
10/20/2005CA2561954A1 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
10/20/2005CA2561952A1 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
10/20/2005CA2561951A1 Extracts of passion fruit and uses thereof
10/20/2005CA2561947A1 Preventives/remedies for cancer
10/20/2005CA2561945A1 Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
10/20/2005CA2561928A1 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
10/20/2005CA2561910A1 Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
10/20/2005CA2561907A1 Composition comprising a jnk inhibitor and cyclosporin
10/20/2005CA2561876A1 Antimicrobial compositions and methods for their use
10/20/2005CA2561801A1 Sulfonamides and uses thereof
10/20/2005CA2561791A1 Non-imidazole heterocyclic compounds
10/20/2005CA2561738A1 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof
10/20/2005CA2561627A1 Oxadiazolone derivatives as ppar delta agonists
10/20/2005CA2561621A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
10/20/2005CA2561619A1 Compositions with reduced hepatotoxicity
10/20/2005CA2561617A1 Histone deacetylase inhibitor prodrugs
10/20/2005CA2561616A1 Sleep-improving composition
10/20/2005CA2561585A1 Imidazol derivatives
10/20/2005CA2561532A1 Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
10/20/2005CA2561292A1 New compositions and methods for maintaining eyelid hygiene
10/20/2005CA2561280A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005CA2561266A1 Pyridyl-substituted porphyrin compounds and methods of use thereof
10/20/2005CA2561249A1 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
10/20/2005CA2561230A1 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof
10/20/2005CA2561210A1 Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
10/20/2005CA2561206A1 Novel diazine derivatives, their manufacture and use as pharmaceutical agents
1 ... 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 ... 7860